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ABSTRACT
S-1 is a combination drug of tegafur, gimeracil and 
oteracil potassium that is designed on the basis of 5- 
fluorouracil. We report here for the first time that S-1 is 
a causative agent of drug eruption mimicking shiitake 
dermatitis. A 58-year-old Japanese man presented with 
pruritic erythemas arranged in a linear fashion. He had 
been treated with S-1 for esophageal cancer. Although 
differential diagnosis included shiitake dermatitis and 
dermatomyositis, he had not eaten raw shiitake mush-
room, and he did not have other cutaneous lesion such 
as Gottron’s sign and abnormalities of peripheral blood 
examination including Jo-1 antibody and antinuclear an-
tibody. Histopathological examination revealed necrotic 
keratinocytes in the Malpighian layer, vacuolar change 
in the basal layer, and lymphocytic and eosinophilic in-
filtration in the upper dermis. Based on clinical and his-
tological findings, we made a diagnosis of drug eruption 
due to S-1. 
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Tegafur/gimeracil/oteracil (S-1) is a combination drug 
that is designed on the basis of 5- fluorouracil (5-FU). 
It is used for treatment of patients with various cancers 
such as gastric, head and neck, lung and pancreatic can-
cers.1–3 S-1 is used as a single agent or in combination 
with platinum-base anticancer drugs such as cisplatin. 
For FU agents, such as 5-FU, tegafur and tegafur/uracil 
(UFT), drug eruptions of discoid lupus erythema-like 
and photosensitive types are well known, but linear 
erythema or scratch dermatitis type is extremely rare.4 
Here we present a rare case of drug eruption due to S-1 
showing a unique skin eruption of linear erythema and 
scratch marks that were almost identical to shiitake der-
matitis. 
PATIENT REPORT
A 58-year-old man presented with pruritic erythemas 
arranged in a linear fashion. He received with S-1 
monotherapy for esophageal cancer. One month after 
administration of the drug, he developed rashes on his 
trunk and extremities. He was referred to us for evalu-
ation. His medications included S-1 and loratadine. On 
physical examination, multiple, pruritic linear erythemas 
and papules were seen on his trunk and extremities (Fig. 
1a). There was no Gottron’s sign, heliotrope rush, elon-
gation of the epionychium or muscle weakness. He had 
no previous history of intake of raw shiitake mushroom. 
Results of peripheral blood examinations including 
Jo-1 antibody and antinuclear antibody were all within 
normal ranges. We did not perform drug-induced lym-
phocyte stimulation test. A skin biopsy specimen taken 
from the upper back revealed necrotic keratinocytes in 
the Malpighian layer, vacuolar change in the basal layer, 
and infiltrate of lymphocytes in the upper dermis inter-
mingled with eosinophils (Fig. 1b). Because of our ten-
tative diagnosis of drug eruption, administration of S-1 
was discontinued. He was treated with topical clobetasol 
ointment and olopatadine. The skin eruption gradually 
improved within 1 month and therapy was discontinued 
without any recurrence of the eruption. However, after 
restarting treatment with S-1, his eruption deteriorated, 
and it was thus concluded that S-1 was the causative 
agent in our patient. 
DISCUSSION
Shiitake dermatitis is caused by the consumption of 
raw shiitake mushroom and it shows flagellate erythe-
ma.5, 6 Histologically, however, our case exhibited ne-
crotic keratinocytes in the epidermis and infiltration of 
lymphocytes and eosinophils in the dermis, suggesting 
a drug eruption rather than shiitake dermatitis, which is 
histologically characterized by a spongiotic epidermis, 
papillary dermal edema and lymphocytic infiltration.6 
Such a necrotic change of keratinocytes had been found 
in acute cutaneous reactions including drug eruptions. 
Bleomycin is a representative drug inducing flagellate 
erythema and the presence of necrotic keratinocytes in 
the epidermis as in our case.7
 Dermatomyositis is also an important differential 
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Fig. 1. a: Physical findings. Linear erythemas and scratch marks were seen on the patient’s trunk.
b: Histopathological findings. Marked necrotic keratinocytes were seen in the Malpighian layer (H&E staining). Bar = 200 μm.
c: Marked necrotic keratinocytes were seen (H&E staining). Bar = 50 μm.
H&E, hematoxylin and eosin.
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diagnosis of linear erythema of trunk. Furthermore, 
dermatomyositis is sometimes related with malignant 
tumor and this patient had esophageal cancer. Histo-
pathologically, liquefaction in basal layer, dermal edema 
and mucin deposition in the dermis are characteristics 
of dermatomyositis. In addition, necrotic keratinocytes 
which were seen in our patient are occasionally found 
in patients with dermatomyositis.8 Therefore, there is a 
possibility of dermatomyositis as a differential diagnosis 
in our patient. However, there was no other cutaneous le-
sion such as Gottron’s sign, heliotrope rush or elongation 
of epionychium, and the result of blood examination did 
not support the diagnosis of dermatomyositis. Thus, we 
excluded the possibility of dermatomyositis.
 Since S-1 is a combination anticancer agent consist-
ing of drugs of tegafur, gimeracil and oteracil potassium, 
we could not specify the causative agent. However, our 
case provided an important implication that an antican-
cer drug, S-1, may show flagellate erythema mimicking 
shiitake dermatitis. 
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